PhillipCapital analyst Tay Wee Kuang has maintained his “accumulate” call on catalist-listed pharmaceutical distributor Hyphens Pharma with an increased target price of 49.5 cents from 43.5 cents previously following the company’s 2Q20/1H20 results.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply